RDIF and Argentina’s Health Ministry joint statement: The preliminary data from a collaborative and multicenter study about vaccine interchangeability was released today and will allow the country to advance in the strategy of using different combinations of doses of vaccines from different platforms, with results similar to the homologous schemes. Individuals may voluntarily opt for combined vaccine schemes.
With the participation of the Russian Direct Investment Fund (RDIF), the study is coordinated by the Ministry of Health of the Nation in collaboration with its counterpart of Science, Technology and Innovation and has the participation of Buenos Aires, Autonomous City of Buenos Aires, Córdoba, La Rioja and San Luis. In addition, it is characterized by being randomized, open, collaborative, and non-inferiority adaptive.
The objectives of the study, which will be a pioneer in the region with regard to the vaccines included in the interchangeability analysis, are to evaluate the immunogenicity and safety of the heterologous vaccination schemes made up of the combination of the vaccines available in Argentina, and to compare the results of immunogenicity and safety with those of the homologous schemes to analyze that are not inferior.
The sample proposes the incorporation of, at least, a total of 1,800 participants from the City of Buenos Aires, province of Buenos Aires, San Luis, Córdoba and La Rioja, and includes volunteers over 18 years of age vaccinated with a dose of Sputnik V, AstraZeneca or Sinopharm vaccine coronavirus up to 60 days prior to enrollment, with and without identified risk factors for COVID-19 that remain in the jurisdiction where the study began until the end of the study.
Message has been successfully sent!
